Skip to content
value.today

Tune Therapeutics, Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2020

Formerly M2X2 Therapeutics, Inc.

Total raised
$182 M
1 round on record
Latest round
$182 M
Mar 2023
First round on record
Mar 2023
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tune Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2023$182 MNo. 1$50 to $250 million

Tune Therapeutics, Inc.: Raise no. 1, Mar 2023

Investors in this round

39 investors had bought by the notice of Jan 24, 2025: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$182 M of $208 M offered; $26 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Akira Matsuno · Executive Officer
  • Blythe Sather · Executive Officer
  • Dan McHugh · Executive Officer, Director
  • Derek Jantz · Executive Officer
  • Yuan Zhang · Executive Officer
  • Zachary Hale · Executive Officer
  • Ali Behbahani · Director
  • Charles Gersbach · Director
  • John McHutchison · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zachary Hale, EVP, General Counsel and Secretary. Source: SEC Form D, newest notice filed Jan 24, 2025. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tune Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2025

That is all the official record says: Tune Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tune Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 39 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tune Therapeutics, Inc.
NameRoleNamed in
Akira MatsunoExecutive officerJan 2025
Blythe SatherExecutive officerJan 2025
Dan McHughExecutive officerJan 2025
Derek JantzExecutive officerJan 2025
Yuan ZhangExecutive officerJan 2025
Zachary HaleExecutive officerJan 2025
Ali BehbahaniDirectorJan 2025
Charles GersbachDirectorJan 2025
Dan McHughDirectorJan 2025
John McHutchisonDirectorJan 2025